Menopause hormone therapy and risk of metabolic syndrome

doi:10.3969/j.issn.1006-7795.2014.04.001

Abstract

Abstract:

The metabolic syndrome (including visceral obesity, dyslipidemia, hyperglycemia, and hypertension) has become one of the major public-health challenges worldwide. The menopause hormone therapy(MHT) is in use for more than a half of century, but the question of indications and ideal candidates for hormone replacement therapy(HRT) remains unclear. Postmenopausal women are a population with the increasing risks for cardiovascular diseases which are the main cause of death in this group. Decline in estrogen concentrations is linked to a number of changes in peri and postmenopause: increased total cholesterol, triglycerides, and low density lipoprotein, increased insulin resistance and increased blood pressure etc. These changes are the main components of metabolic syndrome. HRT is currently recommended as the gold standard for the management of vasomotor symptoms, but the benefit of MHT on components of metabolic syndrome and risk for cardiovascular events risk is still uncertain. This review will focus on MHT risk and benefit issues.

Key words: metabolic syndrome, menopause hormone therapy, obesity, dyslipidaemia, hyperglycaemia, hypertension

CLC Number:

R711

Ruan Xiangyan, Cui Yamei, Diethelm Wallwiener, Alfred O. Mueck. Menopause hormone therapy and risk of metabolic syndrome[J]. Journal of Capital Medical University, 2014, 35(4): 387-391.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2014.04.001

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2014/V35/I4/387

References

[1] Milewicz A. Menopausal obesity and metabolic syndrome PolSenior Study[J]. Minerva Endocrinol, 2012,37(1):93-101.
[2] Yamakawa J, Moriya J, Takahashi T, et al. A kampo medicine, boi-ogi-to, inhibits obesity in ovariectomized rats[J]. Evid Based Complement Alternat Med, 2010,7(1):87-95.
[3] Zoth N, Weigt C, Laudenbach-Leschowski U, et al. Physical activity and estrogen treatment reduce visceral body fat and serum levels of leptinin an additive manner in a diet induced animal model of obesity[J]. J Steroid Biochem Mol Biol, 2010,122(1-3):100-105.
[4] Archer D F, Thorneycroft I H, Foegn M, et al. Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial[J]. Menopause, 2005,12(6):716-727.
[5] Yüksel H, Odabasi A R, Demircan S, et al. Effects of postmenopausal hormone replacement therapy on body fat composition[J]. Gynecol Endocrinol, 2007,23(2):99-104.
[6] Agirbasli M, Agaoglu N B, Orak N, et al. Sex hormones and metabolic syndrome in children and adolescents[J]. Metabolism, 2009,58(9):1256-1262.
[7] Barros R P, Gustafsson J A. Estrogen receptors and the metabolic network[J]. Cell Metab, 2011,14(3):289-299.
[8] Faulds M H, Zhao C, Dahlman-Wright K, et al. The diversity of sex steroid action: regulation of metabolism by estrogen signaling[J]. J Endocrinol, 2012,212(1):3-12.
[9] 张文韬,杨永秀.安今益用于绝经后妇女的激素补充治疗[J].中国计划生育和妇产科,2011,3(1):73-76.
[10] 阮祥燕,闫丹,张俊丽,等.绝经妇女代谢综合征干预措施的研究[J].首都医科大学学报,2013,34(4):519-524.
[11] 刘俊宝,刘晓军,郭晓娟.绝经期雌激素替代治疗对血脂的影响[J].中国妇幼保健,2010,25(21):3014-3015.
[12] 邢玉鉴.围绝经期妇女应用HRT对血脂及骨密度的影响[J].中国实验诊断学,2014,18(2):286-287.
[13] 刘世荣,姚红丽.更年期激素替代治疗对女性脂类代谢的影响[J].中国老年学杂志,2012,32(9):1836-1837.
[14] 田秀娟,盛敏佳,刘俊宝,等.激素替代治疗对绝经后女性心脑血管疾病的影响[J].中国老年学杂志,2009,29(18):2376-2377.
[15] Patrelli T S, Gizzo S, Franchi L, et al. A prospective, case-control study on the lipid profile and the cardiovascular risk of menopausal women on oestrogen plus progestogen therapy in a northern Italy province[J]. Arch Gynecol Obstet, 2013,288(1):91-97.
[16] Korljan B, Bagatin J, Kokic S, et al. The impact of hormone replacement therapy on metabolic syndrome components in perimenopausal women[J]. Med Hypotheses, 2010,74(1):162-163.
[17] Villa P, Suriano R, Ricciardi L, et al. Low-dose estrogen and drospirenone combination: effects on glycoinsulinemic metabolism and other cardiovascular risk factors in healthy postmenopausal women[J]. Fertil Steril, 2011,95(1):158-163.
[18] 朱旅云.内分泌代谢病学科发展现状及设想[J].解放军医药杂志,2013,25(6):1-5.
[19] Samsine G. HRT and cardiovascular disease[J]. Ann N Y Acad Sci, 2003,11(997):358-372.
[20] Salpeter S R, Walsh J M, Ormiston T M, et al. Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women[J]. Diabetes Obes Metab, 2006,8(5):538-554.
[21] 中华医学会妇产科学分会绝经学组.绝经过渡期和绝经后期激素补充治疗临床应用指南(2009版)[J].中华妇产科杂志,2010,45(8):635-638.
[22] Gambacciani M, Rosano G, Cappagli B, et al. Clinical and metabolic effects of drospirenone-estradiol in menopausal women: a prospective study[J]. Climacteric, 2011,14(1):18-24.
[23] Rizzo M R, Leo S, De Franciscis P, et al. Short-term effects of low-dose estrogen/drospirenone vs low-dose estrogen/dydrogesterone on glycemic fluctuations in postmenopausalwomen with metabolic syndrome[J]. Age(Dordr), 2014,36(1):265-274.
[24] 梁鸿寅,王喆,甘立霞.雌激素对胰岛β细胞的作用及其机制[J].医学分子生物学杂志,2008,5(6):535-538.
[25] Langrish J P, Mills N L, Bath L E, et al. Cardiovascular effects of physiological and standard sex steroid replacement regimens in premature ovarian failure[J]. Hypertension, 2009,53(5):805-811.
[26] 杨帆,王广义,张海玉,等.雌激素对更年期大鼠血压的影响[J].中国老年医学杂志,2011,31(9):1615-1616.
[27] Fung M M, Poddar S, Bettencourt R, et al. A cross-sectional and 10-year prospective study of postmenopausal estrogen therapy and blood pressure, renal function, and albuminuria: the Rancho Bernardo Study[J]. Menopause, 2011,18(6):629-637.
[28] Archer D F. Drospirenone and estradiol: a new option for the postmenopausal woman[J]. Climacteric, 2007,10 Suppl 1:3-10.
[29] 殷冬梅,刘真,阮祥燕,等.激素治疗对更年期综合征患者生存质量的影响[J].首都医科大学学报,2013,34(3):428-431.
[30] Moser M. Update on the management of hypertension recent clinical trials and the JNC7[J]. J Clin Hypertens(Greenw ich), 2004,6(10 Suppl 12):4-13.
[31] White W B, Hanes V, Chauhan V B. Effects of a new hormone therapy, drospirenone and 17-β-estradiol in postmenopausal women with hypertension[J]. Hypertension, 2006,48(2):246-253.
[32] Gambacciani M, Rosano G, Cappagli B, et al. Clinical and metabolic effects of drospirenone-estradiol in menopausal women: a prospective study[J]. Climacteric, 2011,14(1):18-24.